BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Allergy Therapeutics plc Release: Anapen® 500mcg Epinephrine Aauto-injector


12/6/2011 8:56:20 AM

6 December 2011 -- Allergy Therapeutics plc (AIM: "AGY"), is pleased to announce that the updated Anapen® 500mcg epinephrine auto-injector device registered in the UK and Ireland will be available in both countries in early 2012. In September the Company obtained the exclusive distribution rights for Anapen® in the UK and Ireland.

As many as one million people in the UK are at risk from anaphylaxis which can be caused by food allergy, insect bites or stings, latex, drugs and other triggers.1,2 The incidence and prevalence of serious allergic reactions such as anaphylaxis are increasing rapidly, as are the number of hospital related admissions.3

The UK’s Resuscitation Council has recommended a dose of 500mcg of epinephrine for adults. The Anapen® 500mcg, produced by Lincoln Medical Limited, is the only 500mcg epinephrine auto-injector currently available in the UK that has been licensed for use in adults with a body weight of 60kg and above. The product is also available in 300mcg and 150mcg doses.

Professor Jonathan Hourihane, Professor of Paediatrics at University College Hospital, Cork commented;

“This is an important development for the community care of adults at risk of anaphylaxis. Delay in receiving appropriate adrenaline is associated with severe adverse outcomes in anaphylaxis and a higher dose auto-injector has long been on the allergists’ wish list for their patients.”

Allergy Therapeutics has been selling Anapen® in The Netherlands since September 2010 and has also received the exclusive rights to distribute Anapen® in Italy, Spain, Belgium, Poland, Argentina, Venezuela, Colombia and Chile; all countries with promising market potential. The Company expects to launch Anapen® in these countries during the next 12 months, subject to regulatory approvals.

For further information:

Allergy Therapeutics

+44 (0) 1903 845 821

Manuel Llobet, CEO

www.allergytherapeutics.com

FTI Consulting

+44 (0) 207 776 1200

Jonathan Birt/ Sue Quigley

Footnotes

1 Resuscitation Council (UK). Emergency treatment for anaphylactic reaction: Guidelines for healthcare providers. January 2008

2 Simons GFE et al. Worold Allergy Organization Guidleines for Assessment and Management of Anaphlaxis. J Allergy Clin Immunol

3 Department of Health. Parliamentary written reply, 26 March 2009. Available at www.theyworkforyou.com/wrans/?id=2009-03-26c.266146.h



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES